Protara Therapeutics, Inc.
TARA- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001359931
In the last 90 days, Protara Therapeutics, Inc. insiders filed 0 open-market purchases and 1 sale; 119 institutions reported holding it in 13F filings for Q2 2026, worth $176.0M in total; no superinvestor holds it.
13F holders, Q2 2024
Institutional positions in Protara Therapeutics, Inc. as of Jun 30, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 38
- +4 vs. Q1 2024
- Shares held
- 10.4M
- +5.88M (+128.6%) vs. Q1 2024
- Total value
- $22.2M
- +$3.89M (+21.2%) vs. Q1 2024
- New holders
- 11
- 14 more added
- Sold out
- 7
- 7 more reduced
Compare with Q1 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting TARA on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 119 | $176.0M |
| Q1 2026 | 114 | $237.4M |
| Q4 2025 | 105 | $212.3M |
| Q3 2025 | 81 | $114.0M |
| Q2 2025 | 76 | $90.1M |
| Q1 2025 | 59 | $123.8M |
| Q4 2024 | 60 | $156.6M |
| Q3 2024 | 35 | $19.1M |
| Q2 2024 | 38 | $22.2M |
| Q1 2024 | 34 | $18.3M |
| Q4 2023 | 30 | $8.17M |
| Q3 2023 | 31 | $8.55M |
| Q2 2023 | 29 | $12.3M |
| Q1 2023 | 29 | $16.9M |
| Q4 2022 | 30 | $14.7M |
| Q3 2022 | 31 | $16.7M |
| Q2 2022 | 33 | $18.4M |
| Q1 2022 | 35 | $33.2M |
| Q4 2021 | 38 | $46.5M |
| Q3 2021 | 36 | $43.7M |
| Q2 2021 | 40 | $69.3M |
| Q1 2021 | 50 | $134.0M |
Institutions, Q2 2024
Shares, value and share of portfolio for each institution holding Protara Therapeutics, Inc.; share changes are against Q1 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Opaleye Management Inc. | 2,304,262 | $5.30M | 1.21% | −388,332−14.4% | Reduced |
| Ra Capital Management, L.P. | 1,900,000 | $3.95M | 0.05% | +1,900,000 | New |
| StemPoint Capital LP | 984,113 | $2.05M | 0.60% | +815,671+484.2% | Added |
| Boxer Capital, LLC | 811,627 | $1.69M | 0.09% | +602,400+287.9% | Added |
| Citadel Advisors LLC | 665,372 | $1.38M | 0.00% | +639,424+2,464.3% | Added |
| Baker Bros. Advisors LP | 536,832 | $1.12M | 0.01% | +337,161+168.9% | Added |
| Armistice Capital, LLC | 520,000 | $1.08M | 0.03% | +520,000 | New |
| Velan Capital Investment Management LP | 480,000 | $998.4K | 0.57% | +480,000 | New |
| Vanguard Group Inc | 427,612 | $889.4K | 0.00% | 00.0% | Unchanged |
| CVI Holdings, LLC | 302,746 | $629.7K | 0.54% | +302,746 | New |
| Ikarian Capital, LLC | 180,712 | $375.9K | 0.12% | −21,989−10.8% | Reduced |
| Two Sigma Investments, LP | 155,773 | $324.0K | 0.00% | +136,025+688.8% | Added |
| Renaissance Technologies LLC | 150,400 | $312.8K | 0.00% | +65,800+77.8% | Added |
| Geode Capital Management, LLC | 140,526 | $292.3K | 0.00% | +57,619+69.5% | Added |
| Oppenheimer & Co Inc | 127,181 | $264.5K | 0.00% | +117,181+1,171.8% | Added |
| BlackRock Inc. | 115,273 | $239.8K | 0.00% | +84,409+273.5% | Added |
| Privium Fund Management (UK) Ltd | 114,708 | $232.9K | 0.09% | −5,022−4.2% | Reduced |
| Woodline Partners LP | 100,001 | $208.0K | 0.00% | +100,001 | New |
| Two Sigma Advisers, LP | 80,518 | $167.5K | 0.00% | +53,500+198.0% | Added |
| Marshall Wace, LLP | 77,351 | $160.9K | 0.00% | +77,351 | New |
| LPL Financial LLC | 44,000 | $91.5K | 0.00% | +16,000+57.1% | Added |
| CIBC World Markets Inc. | 37,000 | $77.0K | 0.00% | +37,000 | New |
| Northern Trust Corp | 28,976 | $60.3K | 0.00% | +11,385+64.7% | Added |
| State Street Corp | 26,600 | $55.3K | 0.00% | 00.0% | Unchanged |
| Bridgeway Capital Management, LLC | 24,200 | $50.3K | 0.00% | −34,800−59.0% | Reduced |
| Boothbay Fund Management, LLC | 20,191 | $42.0K | 0.00% | −2,456−10.8% | Reduced |
| Truist Financial Corp | 20,000 | $41.6K | 0.00% | 00.0% | Unchanged |
| Commonwealth Equity Services, LLC | 19,428 | $40.0K | 0.00% | +19,428 | New |
| Bank of New York Mellon Corp | 17,907 | $37.2K | 0.00% | 00.0% | Unchanged |
| Jane Street Group, LLC | 12,850 | $26.7K | 0.00% | +12,850 | New |
| Susquehanna International Group, LLP | 10,036 | $20.9K | 0.00% | −1,149−10.3% | Reduced |
| Royal Bank of Canada | 6,302 | $13.0K | 0.00% | +2,316+58.1% | Added |
| Tower Research Capital LLC (TRC) | 4,019 | $8.36K | 0.00% | +1,439+55.8% | Added |
| Group One Trading, L.P. | 2,550 | $5.30K | 0.00% | +2,550 | New |
| Wells Fargo & Company | 500 | $1.04K | 0.00% | −70−12.3% | Reduced |
| Bank of America Corp | 149 | $310 | 0.00% | +149 | New |
| Advisor Group Holdings, Inc. | 100 | $208 | 0.00% | 00.0% | Unchanged |
| Qube Research & Technologies Ltd | 2 | $4 | 0.00% | 00.0% | Unchanged |
| Simplex Trading, LLC | 0 | $0 | 0.00% | −17,850−100.0% | Sold out |
| Two Sigma Securities, LLC | 0 | $0 | 0.00% | −17,393−100.0% | Sold out |
| Dimensional Fund Advisors LP | 0 | $0 | 0.00% | −12,126−100.0% | Sold out |
| Acadian Asset Management LLC | 0 | $0 | 0.00% | −6,314−100.0% | Sold out |
| UBS Group AG | 0 | $0 | 0.00% | −3,725−100.0% | Sold out |
| ADAR1 Capital Management, LLC | 0 | $0 | 0.00% | −2,000−100.0% | Sold out |
| JPMorgan Chase & Co | 0 | $0 | 0.00% | −22−100.0% | Sold out |